Gestational diabetes & diabetes in pregnancy
Factors associated with maternal hyperglycaemia and neonatal hypoglycaemia after antenatal betamethasone administration in women with diabetes in pregnancy
Authors' conclusion
An intravenous infusion protocol effectively controls maternal glucose after betamethasone. A risk-factor-based approach may allow individualisation of therapy.
Study context
- Population
- Women with diabetes in pregnancy receiving two doses of 11.4 mg betamethasone 24 h apart (2017–2021), treated with the Pregnancy-IVI intravenous insulin protocol; mean age 31.9 ± 5.8 years; GDM 81%, T1D 12%, T2D 7%
- Participants
- 347 diabetes in pregnancy (DIP) pregnancies
- Outcome
- Maternal glycaemic TIR and maternal insulin requirements after betamethasone; neonatal hypoglycaemia (glucose <2.6 mmol/L) in infants born within 48 h
Methodological detailsconsecutive pregnancies, regression modelling
- Consecutive pregnancies
- Regression modelling
Main finding
As reported in the abstract
On-infusion maternal glucose TIR (4.0-7.8 mmol/L)
On-infusion maternal glucose time-in-range (TIR) (4.0-7.8 mmol/L), IQR 77%-90%
83%
Mean on-IVI glucose (± SD)
6.6 ± 0.5 mmol/L
Observational data: associations, not effects.
Further findings
Neonatal hypoglycaemia (glucose <2.6 mmol/L), infants born within 48 h of betamethasone
- Infants born within 48 h
- 144
- Associated with pre-existing diabetes but not with measures of glycaemic control
Safety
Maternal hypoglycaemia (<3.8 mmol/L)
- Uncommon; h/100 on-IVI woman hours
- 0.47
Original publication
Factors associated with maternal hyperglycaemia and neonatal hypoglycaemia after antenatal betamethasone administration in women with diabetes in pregnancy. Diabet Med. Published 28 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →